Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.60 |
| ▸ | LGALS1 | P09382 | 9/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284264 | 0.86 | LGALS3 (0.80) | LGALS3LGALS1LGALS8 | |
| SCHEMBL3277350 | 0.84 | LGALS3 (0.60) | LGALS3LGALS1LGALS8 | |
| SCHEMBL23005730 | 0.83 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL16258795 | 0.83 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL13404682 | 0.83 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL13385531 | 0.83 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL3276474 | 0.83 | LGALS3 (0.83) | LGALS3LGALS1LGALS8 | |
| SCHEMBL3281942 | 0.82 | LGALS3 (0.68) | LGALS3LGALS1 | |
| SCHEMBL15721140 | 0.81 | LGALS3 (0.62) | LGALS3LGALS1LGALS8 | |
| SCHEMBL3278177 | 0.81 | LGALS3 (0.62) | LGALS3LGALS1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | claimed |
| US-7700763-B2 | 3-triazolyl-galactoside inhibitors of galectins | FORSKARPATENT I SYD AB (SE) | 2010-04-20 | — | — | US | claimed |
| US-20070185041-A1 | NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2007-08-09 | — | — | US | claimed |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | GALECTO BIOTECH AB (DK) | 2017-04-06 | — | — | US | disclosed |
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-12 | — | — | US | disclosed |
| US-7700763-B2 | 3-triazolyl-galactoside inhibitors of galectins | FORSKARPATENT I SYD AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20070185041-A1 | NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320782-A1 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor | LGALS1, LGALS2, LGALS3BP | LGALS3 4/4885LGALS1 1/4885LGALS8 5/4885 |
| US-20170095496-A1 | GALACTOSIDE INHIBITORS FOR NEW USES | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS1 1/4885LGALS8 5/4885 |
| US-20070185041-A1 | NOVEL 3-TRIAZOLYL-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS1 2/4885LGALS8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.